Advertisement
Organisation › Details
Mallinckrodt plc (NYSE: MNK)
Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide and a commercial presence in roughly 65 countries. The company's fiscal 2014 revenue totaled $2.54 billion. *
Start | 2015-03-05 existent | |
Group | Mallinckrodt (Group) | |
Industry | pharmaceutical | |
Industry 2 | contrast medium / imaging agent | |
Person | Trudeau, Mark (Mallinckrodt 201712 CEO) | |
Person 2 | Harbaugh, Matthew (Mallinckrodt 201712 CFO) | |
Region | Dublin | |
Country | Ireland, Republic of | |
City | n. a. | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | G: 5,001 to 10,000 (2015-03-05) |
Currency | USD | |
Annual sales | 2,540,000,000 (revenue (fisacl year 2014)) | |
* Document for »About Section«: | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Mallinckrodt (Group)
- [1] Silence Therapeutics plc. (7/18/19). "Press Release: Silence Therapeutics and Mallinckrodt Announce Collaboration to Develop and Commercialize RNAi Therapeutics for Complement-mediated Diseases". London & Staines-upon-Thames....
- [2] Silence Therapeutics plc. (7/18/19). "Press Release: Mallinckrodt to Make an Equity Investment in Silence Therapeutics as Part of a Collaboration". London & Staines-upon-Thames....
- [3] Pieris Pharmaceuticals, Inc.. (9/10/18). "Press Release: Pieris Pharmaceuticals Appoints Peter Kiener, D.Phil., to its Board of Directors". Boston, MA....
- [4] Mallinckrodt plc. (12/26/17). "Press Release: Mallinckrodt to Acquire Sucampo Pharmaceuticals for approximately $1.2 Billion". Staines-upon-Thames & Rockville, MD....
- [5] Mallinckrodt plc. (12/8/17). "Press Release: Mallinckrodt to Present at 36th Annual J.P. Morgan Healthcare Conference". Staines-upon-Thames....
- [6] Goodwin Procter LLP. (11/2/17). "Press Release: Ocera Therapeutics Acquired by Mallinckrodt for $42 Million"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top